10:41 AM EST - Helius Medical Technologies Inc. : Along with the Tactile Communication and Neurorehabilitation Laboratory of University of Wisconsin-Madison, announced the last subject has been randomized in a 44-subject clinical trial, investigating PoNS™ Therapy for the treatment of chronic balance deficits due to traumatic brain injury (TBI), and the trial is now fully enrolled. Helius Medical Technologies Inc.
shares T.HSM are trading up $0.12 at $2.24.
